The deal ensures that all medicinal products placed on the Community market - including those authorised at purely national level - are subject to the same criteria for the approval and administrative handling of changes, regardless of the procedure under which those medicines have been authorised (national or EU procedure).
Eiropas Parlamenta ziņojums "par uzdevumiem, kas jārisina saistībā ar koplīgumiem ES", pauž apsvērumus par Eiropas Kopienu Tiesas spriedumiem Laval un Partneri, Viking Line, Rüffert un Luksemburgas lietās.